KBY Biotech Indexv0.0.34
Search
← Pipeline|Tixacapivasertib

Tixacapivasertib

Approved
NOX-1145
By Noxopharm
Source: Trial-derived·Trials: 1
Modality
ADC
MOA
CDK4/6i
Target
Tau
Pathway
Innate Imm
Heart FailureMG
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
~Mar 2017
→ ~Jun 2018
Phase 2
~Sep 2018
→ ~Dec 2019
Phase 3
~Mar 2020
→ ~Jun 2021
NDA/BLA
~Sep 2021
→ ~Dec 2022
Approved
Mar 2023
→ Jul 2027
ApprovedCurrent
NCT03540397
1,434 pts·MG
2023-03→2027-07·Not yet recruiting
1,434 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2027-07-081.3y awayPh3 Readout· MG
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
Approved
Not yet…
Catalysts
Ph3 Readout
2027-07-08 · 1.3y away
MG
Not yet recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03540397ApprovedMGNot yet recr...1434MRD
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-5767PfizerPhase 1/2BETCDK4/6i
RHH-1969RocheApprovedBETCDK4/6i
IvocapivasertibBristol-Myers SquibbPhase 1BETCDK4/6i
ZorimavacamtenBristol-Myers SquibbPreclinicalCl18.2CDK4/6i
NVO-9087Novo NordiskPhase 1/2TauCAR-T BCMA
FixatenlimabGSKPhase 1/2JAK1CDK4/6i
TezecilimabTakedaNDA/BLATauBCL-2i
TAK-8262TakedaNDA/BLATauTNFi
VRT-4938Vertex PharmaPreclinicalHER2CDK4/6i
VRT-5441Vertex PharmaPhase 3GLP-1RCDK4/6i